Executive Summary
Third OX2R agonist extending the orexin franchise into neuropsychiatric disorders
ORX489
OX2R · OX2R agonist
Mechanism of Action
TypeSelective OX2R agonist (small molecule)
DescriptionThird-generation OX2R agonist with a profile optimized for neuropsychiatric indications
Indications: Neuropsychiatric disorders
Target Biology
ORX489 targets the same OX2R receptor but is designed for neuropsychiatric conditions. Orexin signaling modulates motivation, reward, mood, and stress responses beyond its role in sleep-wake regulation.
Clinical Data
No clinical trial data available.
Market Opportunity
Catalysts & Upcoming Events
| Event | Timing | Importance | Key Metrics to Watch | Consensus |
|---|---|---|---|---|
| First-in-human clinical studies | 2026 | medium | IND filing and FIH study design | — |